Mark J. Levis
Impact in
- Hematology top 0.01%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 308
- Acute Myeloid Leukemia Research 288
- Chronic Myeloid Leukemia Treatments 173
- Multiple Myeloma Research and Treatments 29
- Genetics 168
- Chronic Lymphocytic Leukemia Research 121
- Myeloproliferative Neoplasms: Diagnosis and Treatment 43
- Co-authors
- Donald Small (63 shared papers)B. Douglas Smith (39 shared papers)Naval Daver (16 shared papers)Alexander E. Perl (74 shared papers)Sabine Käyser (13 shared papers)Keith W. Pratz (40 shared papers)Nigel H. Russell (17 shared papers)Richard F. Schlenk (16 shared papers)
- Journals
- Blood (144 papers)Journal of Clinical Oncology (34 papers)Blood Advances (14 papers)Haematologica (9 papers)Leukemia (9 papers)
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Mark J. Levis
316 papers receiving 14.8k citations
Mark J. Levis's Hit Papers
Peers
Comparison fields: 5 of 109
- Hematology 11.1k
- Genetics 3.8k
- Molecular Biology 6.4k
- Oncology 1.8k
- Public Health, Environmental and Occupational Health 1.9k
Countries citing papers authored by Mark J. Levis
This map shows the geographic impact of Mark J. Levis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Levis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Levis more than expected).
Fields of papers citing papers by Mark J. Levis
This network shows the impact of papers produced by Mark J. Levis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Levis. The network helps show where Mark J. Levis may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark J. Levis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 329 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting FLT3 mutations in AML: review of current knowledge and evidence Hit paper breakdown → | 2019 | 706 |
| 2 | Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia Hit paper breakdown → | 2012 | 559 |
| 3 | Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Hit paper breakdown → | 2004 | 514 |
| 4 | AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Hit paper breakdown → | 2009 | 491 |
| 5 | 2008 | 414 | |
| 6 | 2002 | 396 | |
| 7 | 2003 | 392 | |
| 8 | 2006 | 332 | |
| 9 | 2013 | 296 | |
| 10 | 2010 | 292 | |
| 11 | 2013 | 287 | |
| 12 | 1993 | 275 | |
| 13 | 2017 | 216 | |
| 14 | 2013 | 204 | |
| 15 | 2011 | 196 | |
| 16 | 1992 | 196 | |
| 17 | 2009 | 195 | |
| 18 | 2004 | 192 | |
| 19 | 2004 | 189 | |
| 20 | 2013 | 188 |
About Mark J. Levis
Mark J. Levis is a scholar working on Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health and Oncology, having authored 329 papers that have together received 15.0k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (288 papers), Chronic Myeloid Leukemia Treatments (173 papers), Chronic Lymphocytic Leukemia Research (121 papers), Acute Lymphoblastic Leukemia research (45 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (43 papers), Protein Degradation and Inhibitors (33 papers), Multiple Myeloma Research and Treatments (29 papers) and Retinoids in leukemia and cellular processes (22 papers). The work is most often cited by research in Hematology (11.1k citations), Genetics (3.8k citations), Molecular Biology (6.4k citations), Oncology (1.8k citations) and Public Health, Environmental and Occupational Health (1.9k citations). Mark J. Levis has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Donald Small, B. Douglas Smith, Naval Daver, Alexander E. Perl, Sabine Käyser, Keith W. Pratz, Nigel H. Russell, Richard F. Schlenk, Jörge E. Cortes and Hagop M. Kantarjian. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Haematologica and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.